{"id":"hbvaxpro","rwe":[{"pmid":"36016211","year":"2022","title":"Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients with Chronic Liver Disease in Clinical Practice.","finding":"","journal":"Vaccines","studyType":"Clinical Study"},{"pmid":"34802788","year":"2021","title":"Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).","finding":"","journal":"Vaccine","studyType":"Clinical Study"},{"pmid":"33966331","year":"2021","title":"Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders: Double-blinded, randomised, controlled phase 2 trial.","finding":"","journal":"Liver international : official journal of the International Association for the Study of the Liver","studyType":"Clinical Study"},{"pmid":"33763966","year":"2021","title":"Efficacy of an accelerated double-dose hepatitis B vaccine regimen in patients with cirrhosis.","finding":"","journal":"Journal of viral hepatitis","studyType":"Clinical Study"},{"pmid":"31629649","year":"2020","title":"Serological response to three alternative series of hepatitis B revaccination (Fendrix, Twinrix, and HBVaxPro-40) in healthy non-responders: a multicentre, open-label, randomised, controlled, superiority trial.","finding":"","journal":"The Lancet. Infectious diseases","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Merck Sharp & Dohme LLC","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":["Hepatitis B virus (HBV) vaccine; V232"],"company":"Merck Sharp & Dohme LLC","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HBVAXPRO™","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:07:22.377161+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:07:28.941508+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HBVAXPRO™","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:07:29.746320+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Surface antigen (HBsAg) vaccine antigen","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:07:30.333216+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297973/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:07:30.227478+00:00"}},"allNames":["hbvaxpro™"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Unfortunately, the technical details of hbvaxpro's mechanism of action are not available."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=hbvaxpro%E2%84%A2","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=hbvaxpro™","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:18:01.030928","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:07:32.088506+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"hbvaxpro™","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":["Meningococcal Immunisation","Healthy Volunteers"],"enrollment":1528,"completionDate":"2025-11-15"},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":["Pertussis Immunisation","Diphtheria Immunisation","Polio Immunisation","Hepatitis B Immunisation","Haemophilus Influenzae Type B Immunisation","Tetanus Immunisation","Rotavirus Immunisation","Pneumococcal Immunisation"],"enrollment":460,"completionDate":"2021-11-20"},{"nctId":"NCT06623071","phase":"","title":"Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96/384","status":"RECRUITING","sponsor":"CerbaXpert","startDate":"2024-10-01","conditions":["Hepatitis B"],"enrollment":45,"completionDate":"2025-05-31"},{"nctId":"NCT06800131","phase":"PHASE1","title":"Hepatitis B Vaccine Delivered Trans-dermally by MAP","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2025-02-05","conditions":["Hepatitis B Vaccine"],"enrollment":40,"completionDate":"2026-11-05"},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":["Pneumococcal Infections"],"enrollment":900,"completionDate":"2020-12-14"},{"nctId":"NCT01251276","phase":"PHASE3","title":"Hepatitis B Challenge Dose in Adults (V232-059-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11-30","conditions":["Hepatitis B"],"enrollment":204,"completionDate":"2011-04-12"},{"nctId":"NCT04490499","phase":"PHASE3","title":"A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-09-02","conditions":["Hepatitis B"],"enrollment":207,"completionDate":"2020-12-29"},{"nctId":"NCT04531098","phase":"PHASE3","title":"A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2006-03-02","conditions":["Hepatitis B"],"enrollment":402,"completionDate":"2008-12-31"},{"nctId":"NCT04179786","phase":"PHASE4","title":"A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2015-11-01","conditions":["Hepatitis B"],"enrollment":91,"completionDate":"2017-04-25"},{"nctId":"NCT02555943","phase":"PHASE2,PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":["Chronic Hepatitis C Infection","HBV Coinfection","Hepatitis B Reactivation"],"enrollment":23,"completionDate":"2021-08"},{"nctId":"NCT03408730","phase":"PHASE3","title":"Lot-to-lot Consistency of Sci-B-Vac™ in Adults","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2017-12-14","conditions":["Hepatitis B Vaccines"],"enrollment":2838,"completionDate":"2019-10-01"},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":["Infections, Meningococcal","Meningococcal Vaccines"],"enrollment":2095,"completionDate":"2013-09-10"},{"nctId":"NCT01171989","phase":"PHASE2","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-18","conditions":["Tetanus","Diphtheria","Haemophilus Influenzae Type b","Hepatitis B","Poliomyelitis","Acellular Pertussis","Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni"],"enrollment":391,"completionDate":"2010-12-03"},{"nctId":"NCT01577732","phase":"PHASE3","title":"Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-08","conditions":["Acellular Pertussis","Haemophilus Influenzae Type b","Tetanus","Poliomyelitis","Diphtheria","Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines"],"enrollment":321,"completionDate":"2013-04-09"},{"nctId":"NCT02798952","phase":"PHASE4","title":"A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-23","conditions":["Hepatitis B"],"enrollment":302,"completionDate":"2017-07-05"},{"nctId":"NCT02853929","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-19","conditions":["Diphtheria","Hepatitis B","Acellular Pertussis","Haemophilus Influenzae Type b","Tetanus","Poliomyelitis","Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines"],"enrollment":551,"completionDate":"2019-03-19"},{"nctId":"NCT00637195","phase":"PHASE3","title":"Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-11","conditions":["Infections, Papillomavirus","Papillomavirus Vaccines"],"enrollment":152,"completionDate":"2009-06-18"},{"nctId":"NCT00970307","phase":"PHASE2","title":"Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-13","conditions":["Tetanus","Diphtheria","Haemophilus Influenzae Type b","Poliomyelitis","Acellular Pertussis","Hepatitis B","Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni"],"enrollment":421,"completionDate":"2010-01-27"},{"nctId":"NCT00463437","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-25","conditions":["Hepatitis B","Acellular Pertussis","Tetanus","Poliomyelitis","Diphtheria","Streptococcus Pneumoniae Vaccines"],"enrollment":1437,"completionDate":"2008-06-14"},{"nctId":"NCT01153841","phase":"PHASE3","title":"Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-17","conditions":["Infections, Streptococcal","Streptococcus Pneumoniae Vaccines"],"enrollment":300,"completionDate":"2011-07-26"},{"nctId":"NCT01353703","phase":"PHASE3","title":"Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-16","conditions":["Poliomyelitis","Tetanus","Acellular Pertussis","Haemophilus Influenzae Type b","Diphtheria","Hepatitis B","Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines"],"enrollment":224,"completionDate":"2013-02-25"},{"nctId":"NCT00289731","phase":"PHASE4","title":"Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11-24","conditions":["Hepatitis B","Hepatitis A"],"enrollment":596,"completionDate":"2004-12-21"},{"nctId":"NCT02712177","phase":"","title":"Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2008-08","conditions":["Meningococcal Infections"],"enrollment":4535,"completionDate":"2019-04"},{"nctId":"NCT01345240","phase":"PHASE3","title":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":["Malaria","Malaria Vaccines"],"enrollment":705,"completionDate":"2017-02-09"},{"nctId":"NCT01616459","phase":"PHASE2","title":"Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-11","conditions":["Infections, Streptococcal"],"enrollment":953,"completionDate":"2014-01-22"},{"nctId":"NCT02422264","phase":"PHASE4","title":"Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-01-22","conditions":["Acellular Pertussis","Tetanus","Poliomyelitis","Diphtheria","Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines"],"enrollment":601,"completionDate":"2018-03-07"},{"nctId":"NCT00370396","phase":"PHASE3","title":"Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-25","conditions":["Infections, Streptococcal"],"enrollment":1200,"completionDate":"2007-11-06"},{"nctId":"NCT00343915","phase":"PHASE3","title":"Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-04-21","conditions":["Hepatitis B"],"enrollment":267,"completionDate":"2008-01-10"},{"nctId":"NCT01204658","phase":"PHASE2","title":"Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-27","conditions":["Infections, Streptococcal"],"enrollment":576,"completionDate":"2012-10-01"},{"nctId":"NCT00511095","phase":"PHASE2","title":"Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2007-06","conditions":["Hepatitis B"],"enrollment":207,"completionDate":"2008-03"},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":["Bacterial Infections","Virus Diseases"],"enrollment":1250,"completionDate":"2013-03-13"},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":["Bacterial Infections","Virus Diseases"],"enrollment":1315,"completionDate":"2013-10-09"},{"nctId":"NCT00498212","phase":"PHASE2","title":"A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease","status":"TERMINATED","sponsor":"Dynavax Technologies Corporation","startDate":"2007-07","conditions":["Hepatitis B"],"enrollment":41,"completionDate":"2008-10"},{"nctId":"NCT01195246","phase":"PHASE3","title":"Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-12","conditions":["End Stage Renal Disease"],"enrollment":155,"completionDate":"2012-08"},{"nctId":"NCT02117934","phase":"PHASE3","title":"Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2014-04","conditions":["Healthy"],"enrollment":8374,"completionDate":"2015-10"},{"nctId":"NCT01005407","phase":"PHASE3","title":"Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-02","conditions":["Healthy"],"enrollment":2452,"completionDate":"2011-05"},{"nctId":"NCT00426712","phase":"PHASE1","title":"Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2006-01","conditions":["Hepatitis B"],"enrollment":42,"completionDate":"2008-03"},{"nctId":"NCT00435812","phase":"PHASE3","title":"Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2006-12","conditions":["Hepatitis B"],"enrollment":2428,"completionDate":"2008-03"},{"nctId":"NCT01282762","phase":"","title":"Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-12","conditions":["Chronic Kidney Disease"],"enrollment":147,"completionDate":"2013-08"},{"nctId":"NCT00496015","phase":"PHASE3","title":"Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-02","conditions":["Infections, Streptococcal"],"enrollment":750,"completionDate":"2009-02-17"},{"nctId":"NCT00345358","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-18","conditions":["Infections, Streptococcal"],"enrollment":600,"completionDate":"2007-11-15"},{"nctId":"NCT00513409","phase":"PHASE2","title":"Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-22","conditions":["Infections, Streptococcal"],"enrollment":163,"completionDate":"2008-08-28"},{"nctId":"NCT00390910","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-01","conditions":["Infections, Streptococcal"],"enrollment":286,"completionDate":"2008-05-02"},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":["Bacterial Infections","Virus Diseases"],"enrollment":1473,"completionDate":"2013-05-09"},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":["Bacterial Infections","Virus Diseases"],"enrollment":2808,"completionDate":"2013-07-26"},{"nctId":"NCT01119625","phase":"PHASE3","title":"Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-12","conditions":["Infections, Streptococcal"],"enrollment":238,"completionDate":"2011-02-17"},{"nctId":"NCT00524576","phase":"PHASE4","title":"Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-28","conditions":["Hepatitis B"],"enrollment":144,"completionDate":"2008-05-14"},{"nctId":"NCT01641926","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-26","conditions":["Hepatitis B, Chronic"],"enrollment":402,"completionDate":"2016-01-21"},{"nctId":"NCT00984139","phase":"PHASE4","title":"Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-12","conditions":["Hepatitis B"],"enrollment":306,"completionDate":"2010-04-07"},{"nctId":"NCT01090453","phase":"PHASE2","title":"Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05-17","conditions":["Tetanus","Hepatitis B","Haemophilus Influenzae Type b","Poliomyelitis","Acellular Pertussis","Diphtheria","Neisseria Meningitidis"],"enrollment":480,"completionDate":"2011-10-11"},{"nctId":"NCT01138098","phase":"PHASE4","title":"Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-07","conditions":["Hepatitis B"],"enrollment":185,"completionDate":"2010-11-26"},{"nctId":"NCT01847430","phase":"PHASE4","title":"Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-19","conditions":["Hepatitis B"],"enrollment":303,"completionDate":"2014-02-21"},{"nctId":"NCT00197184","phase":"PHASE3","title":"Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11-01","conditions":["Hepatitis B","Hepatitis A"],"enrollment":276,"completionDate":"2004-03-10"},{"nctId":"NCT00289744","phase":"PHASE3","title":"Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-02-16","conditions":["Hepatitis B","Hepatitis A"],"enrollment":178,"completionDate":"2009-04-15"},{"nctId":"NCT01198769","phase":"PHASE4","title":"Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-11","conditions":["Infections, Rotavirus"],"enrollment":15,"completionDate":"2011-04-18"},{"nctId":"NCT01248884","phase":"PHASE2","title":"Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-09","conditions":["Tetanus","Poliomyelitis","Hepatitis B","Haemophilus Influenzae Type b","Acellular Pertussis","Diphtheria"],"enrollment":721,"completionDate":"2012-01-05"},{"nctId":"NCT00805389","phase":"PHASE2","title":"Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12-15","conditions":["Hepatitis B"],"enrollment":713,"completionDate":"2011-07-14"},{"nctId":"NCT00875485","phase":"PHASE4","title":"Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-01","conditions":["Hepatitis B","Hepatitis A"],"enrollment":210,"completionDate":"2014-07-01"},{"nctId":"NCT00652938","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-09","conditions":["Infections, Papillomavirus"],"enrollment":744,"completionDate":"2010-01-08"},{"nctId":"NCT00578227","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-15","conditions":["Infections, Papillomavirus"],"enrollment":814,"completionDate":"2009-04-28"},{"nctId":"NCT00519649","phase":"PHASE4","title":"Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-31","conditions":["Hepatitis B Vaccine"],"enrollment":301,"completionDate":"2007-12-31"},{"nctId":"NCT00684671","phase":"PHASE4","title":"Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-26","conditions":["Hepatitis A","Hepatitis B"],"enrollment":506,"completionDate":"2008-11-03"},{"nctId":"NCT00289770","phase":"PHASE3","title":"Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-01","conditions":["Hepatitis B","Hepatitis A"],"enrollment":50,"completionDate":"2004-12-20"},{"nctId":"NCT00436007","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-30","conditions":["Malaria"],"enrollment":511,"completionDate":"2009-10-07"},{"nctId":"NCT00317135","phase":"PHASE3","title":"Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12-11","conditions":["Diphtheria","Hepatitis B","Whole Cell Pertussis","Haemophilus Influenzae Type b","Tetanus"],"enrollment":500,"completionDate":"2004-10-23"},{"nctId":"NCT00317187","phase":"PHASE3","title":"Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06-08","conditions":["Hepatitis B","Diphtheria","Whole Cell Pertussis","Tetanus","Haemophilus Influenzae Type b"],"enrollment":500,"completionDate":"2005-01-16"},{"nctId":"NCT02447432","phase":"PHASE3","title":"A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-11","conditions":["Infections, Streptococcal"],"enrollment":320,"completionDate":"2016-05-22"},{"nctId":"NCT01627340","phase":"PHASE4","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-24","conditions":["Hepatitis B"],"enrollment":667,"completionDate":"2013-12-18"},{"nctId":"NCT01463683","phase":"PHASE3","title":"Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-29","conditions":["Hepatitis B"],"enrollment":722,"completionDate":"2012-11-06"},{"nctId":"NCT01000974","phase":"PHASE3","title":"Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-18","conditions":["Haemophilus Influenzae Type b"],"enrollment":4003,"completionDate":"2013-07-17"},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":["Infections, Meningococcal"],"enrollment":461,"completionDate":"2006-03-03"},{"nctId":"NCT00533507","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09-18","conditions":["Infections, Rotavirus"],"enrollment":230,"completionDate":"2008-06-06"},{"nctId":"NCT00871741","phase":"PHASE2","title":"Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-04-01","conditions":["Tetanus","Poliomyelitis","Neisseria Meningitidis","Haemophilus Influenzae Type b","Diphtheria","Acellular Pertussis","Hepatitis B"],"enrollment":16,"completionDate":"2009-06-25"},{"nctId":"NCT00291343","phase":"PHASE3","title":"Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-01","conditions":["Infections, Meningococcal"],"enrollment":296,"completionDate":"2007-03-15"},{"nctId":"NCT02052661","phase":"PHASE4","title":"This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-18","conditions":["Hepatitis B"],"enrollment":301,"completionDate":"2014-09-23"},{"nctId":"NCT00169442","phase":"PHASE3","title":"Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02-10","conditions":["Whole Cell Pertussis","Diphtheria","Hepatitis B","Tetanus","Haemophilus Influenzae Type b"],"enrollment":745,"completionDate":"2006-03-10"},{"nctId":"NCT01449812","phase":"PHASE3","title":"Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-01","conditions":["Acellular Pertussis","Tetanus","Diphtheria","Haemophilus Influenzae Type b"],"enrollment":831,"completionDate":"2012-01-16"},{"nctId":"NCT00627458","phase":"PHASE2","title":"Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-01","conditions":["Acellular Pertussis","Diphtheria","Poliomyelitis","Haemophilus Influenzae Type b","Tetanus","Hepatitis B"],"enrollment":403,"completionDate":"2008-08-18"},{"nctId":"NCT00325143","phase":"PHASE3","title":"Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12-01","conditions":["Haemophilus Influenzae Type b","Diphtheria","Tetanus","Poliomyelitis","Acellular Pertussis"],"enrollment":702,"completionDate":"2007-02-01"},{"nctId":"NCT00158756","phase":"PHASE3","title":"Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-12","conditions":["Hepatitis B"],"enrollment":308,"completionDate":"2006-11-23"},{"nctId":"NCT00317109","phase":"PHASE3","title":"Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-19","conditions":["Infections, Meningococcal"],"enrollment":168,"completionDate":"2007-05-17"},{"nctId":"NCT01333813","phase":"PHASE4","title":"Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-26","conditions":["Hepatitis B"],"enrollment":300,"completionDate":"2011-09-28"},{"nctId":"NCT01086423","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-01","conditions":["Tetanus","Poliomyelitis","Acellular Pertussis","Diphtheria","Haemophilus Influenzae Type b"],"enrollment":985,"completionDate":"2010-11-19"},{"nctId":"NCT00432042","phase":"PHASE3","title":"Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-12","conditions":["Varicella","Measles","Mumps","Rubella","Diphtheria","Tetanus","Pertussis","Poliomyelitis","Hepatitis B","Haemophilus Infections"],"enrollment":955,"completionDate":"2008-03-27"},{"nctId":"NCT00289718","phase":"PHASE3","title":"Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-01","conditions":["Hepatitis B","Hepatitis A"],"enrollment":51,"completionDate":"2005-03-02"},{"nctId":"NCT03128489","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2017-12-01","conditions":["Diphtheria","Acellular Pertussis","Haemophilus Influenzae Type b","Tetanus","Poliomyelitis"],"enrollment":0,"completionDate":"2018-08-01"},{"nctId":"NCT02233075","phase":"PHASE2","title":"REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection","status":"COMPLETED","sponsor":"Replicor Inc.","startDate":"2014-09","conditions":["Chronic HBV Infection (HBeAg Negative)"],"enrollment":12,"completionDate":"2017-05"},{"nctId":"NCT00473668","phase":"PHASE3","title":"Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-01","conditions":["Whole Cell Pertussis","Haemophilus Influenzae Type b","Tetanus","Diphtheria","Hepatitis B"],"enrollment":300,"completionDate":"2008-01-30"},{"nctId":"NCT01457495","phase":"PHASE2","title":"Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1998-09","conditions":["Hepatitis B","Diphtheria","Haemophilus Influenzae Type b (Hib)","Poliomyelitis","Pertussis","Tetanus"],"enrollment":312,"completionDate":"1999-09"},{"nctId":"NCT01457508","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-01","conditions":["Hepatitis B","Diphtheria","Haemophilus Influenzae Type b (Hib)","Poliomyelitis","Pertussis","Tetanus"],"enrollment":440,"completionDate":"2000-03"},{"nctId":"NCT00698061","phase":"PHASE3","title":"Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-11","conditions":["Hepatitis B"],"enrollment":145,"completionDate":"2001-05"},{"nctId":"NCT00414050","phase":"PHASE3","title":"A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-06","conditions":["Hepatitis B"],"enrollment":1718,"completionDate":"2007-10-24"},{"nctId":"NCT02094833","phase":"PHASE3","title":"DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-03","conditions":["Diphtheria","Tetanus","Pertussis","Haemophilus Influenzae Type b Infection","Poliomyelitis","Hepatitis B"],"enrollment":310,"completionDate":"2016-11"},{"nctId":"NCT00197119","phase":"PHASE3","title":"Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05","conditions":["Hepatitis B","Hepatitis A"],"enrollment":244,"completionDate":"2004-06"},{"nctId":"NCT00440531","phase":"PHASE3","title":"Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-11","conditions":["Hepatitis B"],"enrollment":540,"completionDate":"2007-11"},{"nctId":"NCT00440297","phase":"PHASE3","title":"Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":["Hepatitis B Virus Infection"],"enrollment":277,"completionDate":"2008-05"},{"nctId":"NCT00393523","phase":"PHASE3","title":"Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":["Hepatitis B"],"enrollment":1478,"completionDate":"2008-06"},{"nctId":"NCT00383591","phase":"PHASE3","title":"Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-03","conditions":["Hepatitis B"],"enrollment":120,"completionDate":"2004-01"},{"nctId":"NCT00489099","phase":"PHASE3","title":"A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06","conditions":["Hepatitis B Infection"],"enrollment":860,"completionDate":"2006-05"},{"nctId":"NCT00322361","phase":"PHASE2","title":"Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":["Hepatitis B","Hepatocellular Carcinoma"],"enrollment":566,"completionDate":"2007-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL4297973"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Merck Sharp & Dohme LLC","relationship":"Original Developer"}],"publicationCount":24,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"originalDeveloper":"Merck Sharp & Dohme LLC","recentPublications":[{"date":"2022 Aug 16","pmid":"36016211","title":"Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients with Chronic Liver Disease in Clinical Practice.","journal":"Vaccines"},{"date":"2021 Dec 20","pmid":"34802788","title":"Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).","journal":"Vaccine"},{"date":"2021 Oct","pmid":"33966331","title":"Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders: Double-blinded, randomised, controlled phase 2 trial.","journal":"Liver international : official journal of the International Association for the Study of the Liver"},{"date":"2021 Jul","pmid":"33763966","title":"Efficacy of an accelerated double-dose hepatitis B vaccine regimen in patients with cirrhosis.","journal":"Journal of viral hepatitis"},{"date":"2020 Jan","pmid":"31629649","title":"Serological response to three alternative series of hepatitis B revaccination (Fendrix, Twinrix, and HBVaxPro-40) in healthy non-responders: a multicentre, open-label, randomised, controlled, superiority trial.","journal":"The Lancet. Infectious diseases"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"HBVAXPRO™","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:07:32.088506+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}